title: Antiarrhythmic effect of magnesium sulfate against occlusion-induced arrhythmias and reperfusion-induced arrhythmias in anesthetized rats.
abstract: The antiarrhythmic effect of magnesium sulfate (Mg) as well as the hemodynamics were studied using the coronary ligation and reperfusion models in rats. In the study on coronary ligation arrhythmia, i.v. administration of Mg (0.6, 2, 6, 20 and 60 micromol) was conducted at 5 min after coronary ligation. Mg had an action to decrease the total number of premature ventricular contraction (PVC), the duration of ventricular tachycardia (VT), the frequency of VT and ventricular fibrillation (Vf) and the mortality ratio for 30 min after coronary ligation. In the 6-60 micromol groups, significant antiarrhythmic action (p < 0.01 vs. control) was attained. In the study on reperfusion arrhythmia, i.v. administration of Mg (20, 60 and 200 micromol) was conducted at 4 min after coronary ligation, and at 1 min after ligation, the coronary artery was reperfused. Mg had an action to decrease the frequency of Vf, the mortality ratio and the duration of VT and Vf and to extend the interval between the initiation of reperfusion and the occurrence of VT and Vf for 10 min after reperfusion. In the 200 micromol group, significant antiarrhythmic action (p < 0.05 vs. control) was attained. Administration of Mg decreased the heart rate and blood pressure. We concluded that Mg can control myocardial ischemia-induced and reperfusion-induced arrhythmia and that sudden cardiac death which occurs as a result of arrhythmia can be prevented.
authors.affiliation: The Second Department of Medicine, Yamanashi Medical University, Tamaho, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Komori
authors.forename: B
authors.initials: B
authors.lastname: Li
authors.forename: K
authors.initials: K
authors.lastname: Matsumura
authors.forename: M
authors.initials: M
authors.lastname: Takusagawa
authors.forename: S
authors.initials: S
authors.lastname: Sano
authors.forename: I
authors.initials: I
authors.lastname: Kohno
authors.forename: M
authors.initials: M
authors.lastname: Osada
authors.forename: T
authors.initials: T
authors.lastname: Sawanobori
authors.forename: T
authors.initials: T
authors.lastname: Ishihara
authors.forename: K
authors.initials: K
authors.lastname: Umetani
authors.forename: H
authors.initials: H
authors.lastname: Ijiri
authors.forename: K
authors.initials: K
authors.lastname: Tamura
mesh_terms: D000758:Anesthesia; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D002118:Calcium / Q000097:blood; D003331:Coronary Vessels / Q000601:surgery; D006439:Hemodynamics / Q000187:drug effects; D008026:Ligation; D008274:Magnesium / Q000097:blood; D008278:Magnesium Sulfate / Q000494:pharmacology*; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy; D015425:Myocardial Reperfusion / Q000009:adverse effects; D011188:Potassium / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000889:Anti-Arrhythmia Agents; D008278:Magnesium Sulfate; D008274:Magnesium; D011188:Potassium; D002118:Calcium